|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
NLM371948479 |
003 |
DE-627 |
005 |
20240828232221.0 |
007 |
cr uuu---uuuuu |
008 |
240506s2024 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.1080/07366205.2024.2342172
|2 doi
|
028 |
5 |
2 |
|a pubmed24n1515.xml
|
035 |
|
|
|a (DE-627)NLM371948479
|
035 |
|
|
|a (NLM)38706171
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Zorzoli, Azul
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Transitioning from Triton X-100 to Tergitol 15-S-9
|b impacts on diagnostic assays using viral PCR sample solution
|
264 |
|
1 |
|c 2024
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 26.08.2024
|
500 |
|
|
|a Date Revised 27.08.2024
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a In 2019, the European Union banned Triton X-100, a detergent widely used in laboratory diagnostics, including the Viral PCR Sample Solution (VPSS), and urged manufacturers to find environmentally sustainable alternatives. Tergitol 15-S-9 (VPSS2) has been proposed as an alternative surfactant. This multicenter study evaluated the effectiveness of VPSS2, a Tergitol-based viral solution, as a replacement for VPSS. Our results show the equivalent performance of VPSS2 to VPSS for nucleic acid extraction and viral stability over time at different temperatures. The new VPSS formulation was also tested against external quality assurance panels and clinical samples. The results of this work support adopting this modified viral PCR sample solution to replace Triton X-100-containing viral transport solutions
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Multicenter Study
|
650 |
|
4 |
|a SARS-CoV-2
|
650 |
|
4 |
|a Tergitol 15-S-9
|
650 |
|
4 |
|a Triton X-100
|
650 |
|
4 |
|a cycle threshold (Ct)
|
650 |
|
4 |
|a viral load
|
650 |
|
7 |
|a Octoxynol
|2 NLM
|
650 |
|
7 |
|a 9002-93-1
|2 NLM
|
650 |
|
7 |
|a Surface-Active Agents
|2 NLM
|
700 |
1 |
|
|a MacLean, Alasdair
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Nicholson, Scott
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Daniels, Alison
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Hughes, Stephen
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Bennet-Slater, Susan
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Tait-Burkard, Christine
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Sakka, Noha El
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Gunson, Rory
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Templeton, Kate
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t BioTechniques
|d 1988
|g 76(2024), 7 vom: 28., Seite 295-298
|w (DE-627)NLM012627046
|x 1940-9818
|7 nnns
|
773 |
1 |
8 |
|g volume:76
|g year:2024
|g number:7
|g day:28
|g pages:295-298
|
856 |
4 |
0 |
|u http://dx.doi.org/10.1080/07366205.2024.2342172
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_21
|
912 |
|
|
|a GBV_ILN_22
|
912 |
|
|
|a GBV_ILN_39
|
912 |
|
|
|a GBV_ILN_40
|
912 |
|
|
|a GBV_ILN_50
|
912 |
|
|
|a GBV_ILN_60
|
912 |
|
|
|a GBV_ILN_62
|
912 |
|
|
|a GBV_ILN_65
|
912 |
|
|
|a GBV_ILN_70
|
912 |
|
|
|a GBV_ILN_99
|
912 |
|
|
|a GBV_ILN_121
|
912 |
|
|
|a GBV_ILN_130
|
912 |
|
|
|a GBV_ILN_227
|
912 |
|
|
|a GBV_ILN_350
|
912 |
|
|
|a GBV_ILN_618
|
912 |
|
|
|a GBV_ILN_640
|
912 |
|
|
|a GBV_ILN_754
|
912 |
|
|
|a GBV_ILN_2001
|
912 |
|
|
|a GBV_ILN_2002
|
912 |
|
|
|a GBV_ILN_2003
|
912 |
|
|
|a GBV_ILN_2005
|
912 |
|
|
|a GBV_ILN_2006
|
912 |
|
|
|a GBV_ILN_2007
|
912 |
|
|
|a GBV_ILN_2008
|
912 |
|
|
|a GBV_ILN_2009
|
912 |
|
|
|a GBV_ILN_2010
|
912 |
|
|
|a GBV_ILN_2012
|
912 |
|
|
|a GBV_ILN_2015
|
912 |
|
|
|a GBV_ILN_2018
|
912 |
|
|
|a GBV_ILN_2023
|
912 |
|
|
|a GBV_ILN_2035
|
912 |
|
|
|a GBV_ILN_2040
|
912 |
|
|
|a GBV_ILN_2060
|
912 |
|
|
|a GBV_ILN_2099
|
912 |
|
|
|a GBV_ILN_2105
|
912 |
|
|
|a GBV_ILN_2121
|
912 |
|
|
|a GBV_ILN_2470
|
951 |
|
|
|a AR
|
952 |
|
|
|d 76
|j 2024
|e 7
|b 28
|h 295-298
|